Also found in: Dictionary.
Related to Dovonex: Dovobet


(kal-si-poe-try-een) ,


(trade name),


(trade name)


Therapeutic: antipsoriatics
Pharmacologic: synthetic vitamin d3 analogues
Pregnancy Category: C


Management of plaque psoriasis.


Modulates skin cell development and production by acting as a synthetic form of vitamin D.

Therapeutic effects

Decreased extent and severity of psoriatic lesions.


Absorption: 6% (cream and ointment) and 1% (scalp solution) is systemically absorbed from psoriatic lesions.
Distribution: Unknown.
Metabolism and Excretion: Metabolized and recycled by the liver; excreted in bile.
Half-life: Unknown.

Time/action profile (improvement in psoriatic lesions)

Topical2–8 wkunknownunknown


Contraindicated in: Hypersensitivity to calcipotriene or other components in the base (petrolatum and mineral oil in cream (U.S.), propylene glycol in scalp solution (U.S.), paraffin in Canadian product); Hypercalcemia; Vitamin D toxicity.
Use Cautiously in: Geriatric: ↑ incidence of local reactions; Obstetric / Lactation / Pediatric: Safety not established.

Adverse Reactions/Side Effects


  • burning (most frequent)
  • itching (most frequent)
  • skin irritation (most frequent)
  • dry skin
  • erythema
  • peeling
  • rash
  • worsening/spreading of psoriatic lesions

Fluid and Electrolyte

  • hypercalcemia


Drug-Drug interaction

None significant at recommended doses.


Topical (Adults) Apply twice daily.

Availability (generic available)

Cream: 0.005%
Ointment: 0.005%
Scalp solution: 0.005%
Foam: 0.005%
In combination with: betamethasone dipropionate (Taclonex).

Nursing implications

Nursing assessment

  • Assess skin before and periodically during therapy.
  • Lab Test Considerations: Monitor serum calcium concentrations before and periodically during therapy. May cause transient, rapidly reversible hypercalcemia. If hypercalcemia occurs, discontinue calcipotriene and monitor calcium levels weekly until normal serum calcium levels are restored.
  • Excessive use may cause hypercalcemia because sufficient amounts may be absorbed from topical application.

Potential Nursing Diagnoses

Risk for impaired skin integrity (Indications)
Disturbed body image (Indications)
Deficient knowledge, related to medication regimen (Patient/Family Teaching)


  • Topical: Apply a thin layer to affected skin twice daily and rub in gently and completely. Apply sparingly in skin folds to prevent irritation from natural occlusion. Do not apply occlusive dressings. If calcipotriene is used in combination with ultraviolet B light (UVB) phototherapy, apply calcipotriene after phototherapy.
    • For solution, prepare scalp before applying by combing and removing scaly debris and parting hair for easy access to scalp lesions. Apply only to visible scalp lesions and rub in gently and completely. Do not apply to acute psoriatic eruptions.

Patient/Family Teaching

  • Instruct patient to use medication as directed. If a dose is missed, apply as soon as possible, unless almost time for next dose. Calcipotriene is for external use only; contact with face or eyes should be avoided. Wash hands after application.
  • Advise patient not to use calcipotriene for any disorder other than that for which it was prescribed.
  • Instruct patient to report any signs of local adverse reactions, persistent irritation, or facial rash to health care professional. Calcipotriene may cause irritation of lesions and surrounding skin. Discontinuation of the drug may be required.
  • Advise patient to avoid excessive exposure of natural or artificial light to treated area.
  • Emphasize the importance of regular lab tests to monitor calcium concentrations.
  • Instruct patient to consult health care professional if skin problem has not improved within 2–8 wk or if skin condition worsens.

Evaluation/Desired Outcomes

  • Improvement or resolution of skin lesions in psoriasis. Improvement usually begins after 2 wk of therapy, with marked improvement by 8 wk.


A topical vitamin-D analogue with minimum effects on vitamin-D metabolism, which is FDA-approved for treating mild-to-moderate psoriasis; it is similar in efficacy to topical corticosteroids.

Adverse effects
Rarely, hypercalcaemia.


A brand name for CALCIPOTRIOL.
References in periodicals archive ?
From the closing of the LEO Transaction on September 23, 2009 until LEO assumed responsibility for its own distribution services on June 30, 2010, we recorded net sales (and cost of sales) for all TACLONEX and DOVONEX products sold in the United States at nominal distributor margins pursuant to the distribution agreement executed in connection with the LEO Transaction.
From the closing of the LEO Transaction on September 23, 2009 until LEO assumed responsibility for its own distribution services on June 30, 2010, the Company recorded net sales (and cost of sales at nominal distributor margins) for all TACLONEX and DOVONEX products sold in the United States pursuant to the distribution agreement executed in connection with the LEO Transaction.
0 million primarily due to the new DOVONEX and TACLONEX inventories which lowered the cash flows from operating activities.
0 million of costs for DOVONEX and TACLONEX products which were distributed at nominal distributor margins under the LEO distribution agreement.
Also contributing to the increase in the current year were higher costs relative to the prior year, partially offset by the absence of a 5% royalty on our net sales of DOVONEX which we were required to pay in the prior year under a contract with Bristol-Myers that terminated on December 31, 2007.
More stubborn cases may need a steroid lotion or Dovonex shampoo, which are available on prescription.
10 Dovonex Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Previously, Dovonex (calcipotriene) cream and scalp solution (Leo Pharmaceutical Products) were the only topical vitamin D formulations approved for psoriasis treatment in the United States.
Some of products expected to come off patent in 2008 include Sarafem for premenstrual dysphoric disorder, Depakote for seizures, Cipro HC for external ear infections, and Dovonex for psoriasis.
Psoriasis Immune system Patches of Phototherapy, triggers an raised, reddish topical medications increased growth skin covered by including cycle of skin silvery-white Drithocreme cells, leading scales that form (anthralin), to overgrowth of on the elbows, Dovonex cells and knees, lower (calcipotriene), lesions.
Thirty six pharmacists would have supplied Dovonex cream to a German Shepherd dog.